📊 BEAM Key Takeaways
Is Beam Therapeutics Inc. (BEAM) a Good Investment?
Beam Therapeutics demonstrates strong revenue momentum (+120% YoY) with a fortress balance sheet ($288.3M cash, 0.09x debt/equity), but faces critical execution risk from severe operating losses (-$107.2M) and negative free cash flow (-$130.7M) that consume ~2-2.5 years of cash runway. Investment hinges on commercialization acceleration and achieving gross margin expansion to offset current operating inefficiency.
Beam Therapeutics shows strong balance-sheet quality with substantial equity, no long-term debt, and exceptional liquidity, which materially reduces near-term financing risk. However, the business remains deeply unprofitable, with very negative operating margins and free cash flow, so the recent revenue surge does not yet translate into durable earnings quality. Fundamentally, this looks like a well-capitalized but still cash-burning biotech that needs clearer operating leverage and more sustainable revenue conversion to justify a more positive stance.
Beam Therapeutics Inc. Key Strengths (BEAM)
- Exceptional revenue growth of 120% YoY indicating successful product commercialization and market acceptance
- Fortress balance sheet with $288.3M in cash and minimal debt burden (0.09x debt/equity ratio) providing years of operational runway
- Excellent liquidity position (16.99x current ratio) enabling flexibility to fund R&D, commercialization, and potential acquisitions without capital constraints
- Very strong liquidity profile with 13.09x current and quick ratios
- Debt-free capital structure and large equity base support financial flexibility
- Revenue grew 120% year over year, indicating meaningful top-line progress
BEAM Stock Risks: Beam Therapeutics Inc. Investment Risks
- Severe operating cash burn of -$128.5M annually with approximately 2-2.5 years of cash runway requiring near-term profitability milestone achievement
- Deeply unprofitable operations with -337.8% operating margin indicating inability to scale revenue efficiently and generate positive unit economics
- Uncertain path to profitability absent demonstrated gross margin expansion and operational leverage improvement despite revenue growth
- Operating losses remain severe, with operating margin at -274.6%
- Free cash flow is deeply negative at -$360.05M, implying continued cash burn
- Revenue quality may be less durable if growth is driven by non-recurring collaboration or milestone activity rather than a broad commercial base
Key Metrics to Watch
- Quarterly operating cash flow burn rate and timeline to cash flow breakeven
- Revenue growth sustainability and gross margin percentage progression toward positive operating income
- Clinical pipeline advancement milestones and product adoption rates determining near-term revenue acceleration potential
- Quarterly operating cash burn relative to cash and equivalents
- Revenue durability and whether operating margin improves meaningfully over time
Beam Therapeutics Inc. (BEAM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 16.99x current ratio provides a solid financial cushion.
BEAM Profit Margin, ROE & Profitability Analysis
BEAM vs Healthcare Sector: How Beam Therapeutics Inc. Compares
How Beam Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Beam Therapeutics Inc. Stock Overvalued? BEAM Valuation Analysis 2026
Based on fundamental analysis, Beam Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Beam Therapeutics Inc. Balance Sheet: BEAM Debt, Cash & Liquidity
BEAM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Beam Therapeutics Inc.'s revenue has grown significantly by 629% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.72 indicates the company is currently unprofitable.
BEAM Revenue Growth, EPS Growth & YoY Performance
BEAM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $7.5M | -$94.3M | $-0.91 |
| Q3 2025 | $9.7M | -$91.1M | $-1.10 |
| Q2 2025 | $8.5M | -$91.1M | $-1.00 |
| Q1 2025 | $7.4M | -$98.7M | $-1.21 |
| Q3 2024 | $14.3M | -$82.8M | $-1.17 |
| Q2 2024 | $11.8M | -$82.8M | $-1.08 |
| Q1 2024 | $7.4M | -$96.5M | $-1.21 |
| Q3 2023 | $15.8M | -$69.2M | $-1.22 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Beam Therapeutics Inc. Dividends, Buybacks & Capital Allocation
BEAM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Beam Therapeutics Inc. (CIK: 0001745999)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BEAM
What is the AI rating for BEAM?
Beam Therapeutics Inc. (BEAM) has a Combined AI Grade of B from Claude (B) and ChatGPT (B) with 73% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BEAM's key strengths?
Claude: Exceptional revenue growth of 120% YoY indicating successful product commercialization and market acceptance. Fortress balance sheet with $288.3M in cash and minimal debt burden (0.09x debt/equity ratio) providing years of operational runway. ChatGPT: Very strong liquidity profile with 13.09x current and quick ratios. Debt-free capital structure and large equity base support financial flexibility.
What are the risks of investing in BEAM?
Claude: Severe operating cash burn of -$128.5M annually with approximately 2-2.5 years of cash runway requiring near-term profitability milestone achievement. Deeply unprofitable operations with -337.8% operating margin indicating inability to scale revenue efficiently and generate positive unit economics. ChatGPT: Operating losses remain severe, with operating margin at -274.6%. Free cash flow is deeply negative at -$360.05M, implying continued cash burn.
What is BEAM's revenue and growth?
Beam Therapeutics Inc. reported revenue of $31.7M.
Does BEAM pay dividends?
Beam Therapeutics Inc. does not currently pay dividends.
Where can I find BEAM SEC filings?
Official SEC filings for Beam Therapeutics Inc. (CIK: 0001745999) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BEAM's EPS?
Beam Therapeutics Inc. has a diluted EPS of $-0.91.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BEAM's fundamental grade?
Based on our AI fundamental analysis in June 2026, Beam Therapeutics Inc. has a B grade with 73% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BEAM stock overvalued or undervalued?
Valuation metrics for BEAM: ROE of -8.1% (sector avg: 15%), net margin of -297.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BEAM's AI grade for 2026?
Our dual AI analysis gives Beam Therapeutics Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BEAM's free cash flow?
Beam Therapeutics Inc.'s operating cash flow is $-128.5M, with capital expenditures of $2.2M. FCF margin is -412.0%.
How does BEAM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -297.2% (avg: 12%), ROE -8.1% (avg: 15%), current ratio 16.99 (avg: 2).